20:45 , Jun 13, 2019 |  BC Extra  |  Financial News

June 13 Financial Quick Takes: Hansoh prices $1B HKEX IPO; plus Provention, Genome Medical, InGeneron and more

Hansoh gets $10B-plus valuation via Hong Kong IPO  Hansoh Pharmaceutical Group Co. Ltd. (HKSE:03692) priced its Hong Kong IPO Thursday, raising HK$7.9 billion ($1 billion) through the sale of 551.3 million shares at HK$14.26. The...
01:04 , Jun 11, 2019 |  BC Extra  |  Company News

Why Brii Bio partnered with microbiome start-up Artizan

In its latest move to bring innovation to infectious diseases in China, Brii Bio has partnered with microbiome start-up Artizan, which is approaching IBD as if it were an infectious disease. Artizan Biosciences Inc. (New...
21:57 , Jun 10, 2019 |  BC Extra  |  Politics & Policy

Stakeholders back Medicare Part D out-of-pocket cap, call for additional changes to lower patient costs

The biopharmaceutical industry, patient groups, PBMs and other stakeholders have endorsed proposals to cap out-of-pocket drug costs for Medicare Part D beneficiaries in comments submitted to the House Ways and Means and Energy and Commerce...
22:45 , Jun 7, 2019 |  BC Innovations  |  Distillery Therapeutics

CRISPR-edited B cells treat RSV

DISEASE CATEGORY: Infectious disease INDICATION: Respiratory syncytial virus (RSV) Mouse studies suggest CRISPR-edited B cells that secrete engineered anti-RSV F protein antibodies could help treat RSV infection. Generation of the cells involves editing primary B...
10:52 , Jun 7, 2019 |  BC Extra  |  Company News

As Sanofi enters growth phase, Novartis exec Hudson to take the helm

Novartis has lost one executive from each of its Innovative Medicines units in the span of three days, now that Sanofi has named seasoned British sales and marketing executive Paul Hudson as the successor to...
03:07 , Jun 7, 2019 |  BC Innovations  |  Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
02:26 , Jun 3, 2019 |  BC Extra  |  Clinical News

Lynparza shows PFS benefit of 3.6 months in pancreatic cancer

AstraZeneca’s Lynparza olaparib has hit the minimum three-month benefit that oncologists were hoping to see in pancreatic cancer. Data presented Sunday at ASCO position the PARP inhibitor to become the first targeted agent to treat...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
01:12 , Jun 1, 2019 |  BioCentury  |  Product Development

Clinical trial and regulatory efficiency get help from ctDNA, RWE at ASCO19

This year’s crop of ASCO abstracts show companies are going full bore on pre- and post-market technologies that can speed up development and regulatory timelines. In BioCentury’s analysis of 4,627 abstracts, over 500 feature circulating...
23:52 , May 30, 2019 |  BC Innovations  |  Emerging Company Profile

Aro delivers bispecifics, siRNAs where others can’t

A year after its launch, Susan Dillon and Karyn O’Neil’s Aro has begun to reveal details about how the J&J spinout’s Centyrins could form small bispecifics and stable siRNA therapies to penetrate hard-to-reach cancers. Therapies...